If you’re a patient or caregiver please get in touch

We are currently enrolling people with a genetic sub-type of frontotemporal dementia (FTD-GRN) into our ASPIRE-FTD Phase 1/2 open-label, multi-center study designed to evaluate the safety and preliminary efficacy of *investigational gene therapy AVB-101 in patients with FTD-GRN.

CLINICAL SITE INFORMATION

For more information on ASPIRE-FTD including a list of active clinical sites please visit here or clinicaltrials.gov.

CONTACT US

You can also contact us by phone US/International +1 (888) 591 8117, UK +44 (0) 203 089 7917 or via email clinicaltrials@aviadobio.com.

*Investigational therapy means that the therapy has not been approved by any regulatory authority and no regulatory authority has determined the therapy to be safe and effective to treat FTD-GRN or any other condition.